Vanda Pharmaceuticals Stock Fades After Hetlioz Sleep-Trial News
Vanda Pharmaceuticals (VNDA) shares initially rose 3% on Wednesday following a late Tuesday update on its Hetlioz drug for delayed sleep-wake phase disorder. However, the stock gave up all gains as investors weighed the small trial population and potential generic competition.